Please ensure Javascript is enabled for purposes of website accessibility

Why GoodRx Holdings Trounced the Market Today

By Eric Volkman – Aug 12, 2021 at 6:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The discount-medications specialist looks set to benefit from a return to the doctor's office for many customers.

What happened

On Thursday, GoodRx Holdings (GDRX -0.45%) was very good for any ailing stock portfolio. The discount-medications supplier saw its shares rise by nearly 15% following the release of its Q2 results.

So what

GoodRx's revenue for the quarter came in at $176.6 million, a 43% year-over-year improvement that was on the back of 86% growth in the company's number of subscription plans. Of that total, nearly $145 million derived from prescription transactions, a core activity for the online discount pharmacy. The remainder was more or less divided between subscription revenue and "other" areas, including telehealth services.

An elderly customer at a pharmacy.

Image source: Getty Images.

The company's non-GAAP (adjusted) net income, meanwhile, rose by 9% over that stretch of time to land at $35.1 million ($0.08 per diluted share).

Interestingly, analysts tracking the stock had collectively estimated $174.7 million in revenue, so the company beat only modestly on the top line. As for profitability, that $0.08 per share essentially met prognosticator expectations.

Now what

GoodRx also proffered fresh revenue guidance for its current Q3. The company believes it will earn $193 million to $197 million in revenue. The average analyst estimate for the quarter lands almost squarely in the middle, at just under $192.2 million. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) should come in at around 30% of revenue. No bottom-line forecasts were provided.

This was hardly a blowout quarter for GoodRx, but investors might be cheered by management's observation that many people continue to delay doctor visits due to the resurgent coronavirus. So when and if this subsides, a return to the examination room could really improve GoodRx's performance.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends GoodRx Holdings, Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GoodRx Holdings, Inc. Stock Quote
GoodRx Holdings, Inc.
$4.44 (-0.45%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.